Certara, Inc. (CERT) Stock Price & Analysis

Certara, Inc. (CERT) fell 0.77% to USD 5.18 as of June 9, 2026 at 23:51 UTC, according to Nexqual real-time market data.

CERT last closed at USD 5.22; the session ranged USD 5.14–5.46 on volume of 4,341,087 shares. Market capitalization is $805.82M, with a 52-week range of USD 4.45–13.88 (NMS). Source: Nexqual, June 9, 2026 at 23:51 UTC.

Key Statistics (as of June 9, 2026 at 23:51 UTC)

Technical Analysis (CERT)

Nexqual's technical model rates CERT "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:51 UTC.

Analyst Ratings (CERT)

Wall Street analysts rate CERT "Buy" based on 11 analysts, with a mean price target of USD 7.62 (range USD 6–10), per Nexqual as of June 9, 2026 at 23:51 UTC.

Earnings (CERT)

Recent Earnings History

Source: Nexqual, June 9, 2026 at 23:51 UTC.

Financials & Fundamentals (CERT)

Source: Nexqual, June 9, 2026 at 23:51 UTC.

Financial Health Score (CERT)

Nexqual rates Certara, Inc.'s overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:51 UTC.

Ownership (CERT)

Source: Nexqual, June 9, 2026 at 23:51 UTC.

Leadership (CERT)

Certara, Inc. is led by Jon Resnick (age 52), CEO & Director, per Nexqual as of June 9, 2026 at 23:51 UTC.

Major Backers & Investors (CERT)

Notable institutional backers of Certara, Inc. include Deerfield Management Company, L.P, Jefferies Financial Group Inc., Wasatch Advisors LP, according to Nexqual as of June 9, 2026 at 23:51 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 9, 2026 at 23:51 UTC.

From Certara, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our software products are licensed by more than 160,000 users and are also used by 20 global drug regulatory agencies, including the FDA, Japan's Pharmaceuticals and Medical 7 Table of Contents Devices Agency (the "PMDA"), and China's Center for Drug Evaluation (the "CDE") within the National Medical Product Administration (the "NMPA").
• Since 2013, we have acquired 21 companies, 14 of which include software or technology, with such key acquisitions including Simcyp, the core of our mechanistic biosimulation platform, Pinnacle 21, which enhances our software offerings in data management and the regulatory drug approval process, and Vyasa, which brings state-of-the-art AI capabilities to our end-to-end platform.
• The pharmaceutical industry spends more than $290 billion annually on research and development.
• Phoenix has four modules that support pharmacometrics and workflow. • Phoenix WinNonlin – A platform for non-compartmental analysis, PK/PD, and TK modeling with a regulatory proven 30-year history and extensive use across the biopharmaceutics industry. • Phoenix Cloud – Our next generation cloud version of Phoenix, which provides a secured and validated Certara Amazon Web Services ("AWS") workspace allowing for much quicker transit time from compliant data sources.

Partnerships

• It provides researchers with industry leading self-service data access, comprehensive data visualizations, analysis and collaboration tools for prioritization, development of Structure Activity Relationship ("SAR") and many other scientific data workflows to improve the effectiveness of data-driven research.
• With greater investment dollars being spent and increasing competition in the race to develop novel medicines, the speed and efficiency with which drugs are developed and brought to market have never been more critical.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:51 UTC. This page is informational and not investment advice.